Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-MG trial of pyridostigmine and add-on amifampridine in acetylcholine receptor-positive myasthenia gravis
NL-OMON54093Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pyridostigmine and amifampridine in myasthenia gravis (MG) (5 arms), sponsored by Leiden University Medical Center. Primary endpoint: Primary efficacy endpoint. Started Mar 2023; status: completed.
02
Drugs
pyridostigmineamifampridine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON54093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54093.